Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Inter-Regional Epidemiological Study of Childhood Cancer (IRESCC): Childhood cancer and the consumption of Debendox and related drugs in pregnancy

Abstract

Attention has recently focused on the possible teratogenic effects of the combination antiemetic doxylamine succinate, dicyclomine hydrochloride and pyridoxine hydrochloride (Debendox/Bendectin) prescribed to pregnant women. The Inter-Regional Epidemiological Study of Childhood Cancer (IRESCC), a case-control investigation has analysed data derived from interview reports and medical records of 555 mothers of children (under 15 years) with cancer and 1110 mothers of matched control children. Separate analyses of interview reports and medical records both suggested that antiemetic ingestion during the index pregnancy does not increase the risk of developing childhood malignant disease in the exposed foetus. No dose-response relationship was evident. The lack of any significant relative risks held good for diagnostic sub-groups and when the trimester of ingestion was considered. Our results suggest that antimetics of this type are unlikely to be transplacental carcinogens.

This is a preview of subscription content, access via your institution

Access options

Buy this article

Prices may be subject to local taxes which are calculated during checkout

Similar content being viewed by others

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

McKinney, P., Cartwright, R., Stiller, C. et al. Inter-Regional Epidemiological Study of Childhood Cancer (IRESCC): Childhood cancer and the consumption of Debendox and related drugs in pregnancy. Br J Cancer 52, 923–929 (1985). https://doi.org/10.1038/bjc.1985.278

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1038/bjc.1985.278

This article is cited by

Search

Quick links